Data Supplement
Files in this Data Supplement:
- Supplemental Data -
Supplementary Figure 1 - (Supplementary to figure 1.) Changes in CFTR surface expression in untransfected BHK cells (parental) and BHK cells expressing wild-type CFTR...
Supplementary Figure 2 - (Supplementary to Figure 2) Test of the level of cell death upon 24-hour treatment with various concentrations of MCG315
Supplementary Figure 3 - Supplementary to figure 3.) PARP enzyme activity of various members of the PARP family
Supplementary Figure 4 - (Supplementary to Figure 3) PARP enzyme activity of various members of the PARP family in the presence of various concentrations of laronduine and MCG315
Supplementary Figure 5 - (Supplementary to Figures 4 and 6
Supplementary Figure 6 - (Supplementary to Figure 5.) PARP-16 ribosylation of IRE-1 and its inhibition by various concentrations of MCG315 measured by 32P incorporation of NAD
Supplementary Figure 7 - (A. and B. is supplementary to figure 4: C. is supplementary to Figure 6.) A. Immunoprecipitation of IRE-1 from cells treated with tunicamycin (3μg/ml)(4 hours) to stimulate the UPR in the presence and absence of MCG315
Supplementary Figure 8 - Test of the effect of latonduine analogues on the surface expression of CD44 and on the expression of selected protein trafficking pathway markers
Supplementary Figure 9 - (Supplementary to figure 4). To test if there is a link between PARP-1 inhibition mediated CFTR correction and latonduine family mediated CFTR correction
Supplementary Table 1 - (Supplementary to Figure 3 and supplementary Figure 4) The IC50 s for latonduine, MCG315 and PJ34 to inhibit various members of the PARP family (PARPs 1, 2, 3, 4, 5A, 5B, 11 and 16)
SUPPLEMENTARY METHODS
SUPPLEMENTAL DATA FILE